<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1129">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01840605</url>
  </required_header>
  <id_info>
    <org_study_id>TAU-284-19</org_study_id>
    <nct_id>NCT01840605</nct_id>
  </id_info>
  <brief_title>A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis</brief_title>
  <official_title>A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (Ketotifen Fumarate-controlled, Double-blind, Comparative Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to verify the non-inferiority of TAU-284 to ketotifen
      fumarate dry syrup in the change in the severity of pruritus after the treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, parallel-group comparative study to demonstrate the
      noninferiority of TAU-284 to ketotifen fumarate in pediatric patients with atopic
      dermatitis, as assessed by the primary endpoint of the change from baseline in pruritus
      score after 2-week treatment with TAU-284 (20 mg/day) or ketotifen fumarate dry syrup (2
      g/day); and to investigate the safety, and plasma concentrations of TAU-284.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Pruritus Score</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The pruritus symptoms score were rated on 5-point scale ranging from 0 (none) to 4 (severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pruritus Score</measure>
    <time_frame>2 ｗeeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Atopic Dermatitis</measure>
    <time_frame>2 ｗeeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Impression of Pruritus</measure>
    <time_frame>2 ｗeeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Dermatitis</condition>
  <condition>Atopic</condition>
  <arm_group>
    <arm_group_label>TAU-284</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day, once after breakfast and once before bed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketotifen fumarate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two TAU-284 5mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day, once after breakfast and once before bed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bepotastine besilate</intervention_name>
    <description>Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day</description>
    <arm_group_label>TAU-284</arm_group_label>
    <other_name>TALION 5mg tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketotifen fumarate</intervention_name>
    <description>Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day</description>
    <arm_group_label>ketotifen fumarate</arm_group_label>
    <other_name>ketotifen fumarate dry syrup</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 7 and 15 years

          -  Patients giving assent and whose legal guardian giving informed consent

          -  Outpatients

          -  Patients diagnosed as atopic dermatitis

          -  Patients who require the treatment with topical corticosteroid on areas other than
             face, head and neck

          -  Patients whose diaries can be properly maintained

          -  Patients who have 2 grades or more pruritus score

        Exclusion Criteria:

          -  Patients with bronchial asthma who require concomitant use of the corticosteroid

          -  Patients who have been undergoing specific desensitization therapy or nonspecific
             immunomodulation therapy or phototherapy

          -  Patients with current or previous history of drug hypersensitivity

          -  Patients who have been treated with Bepotastine besilate in the past

          -  Patients who have; a skin infection, or with zooparasite such as scabies and
             pediculosis; eczematous otitis externa with perforation in the eardrum; dermal ulcer,
             or profound heat burn or frostbite of the severity higher than the grade 2; on areas
             where topical corticosteroid is applied

          -  Patients who have spastic disease such as epilepsy

          -  Patients who concurrently have renal function abnormalities that may cause safety
             problems

          -  Patients who do not give consent to use birth control

          -  Pregnant patients, at risk of pregnancy or breastfeeding

          -  Patients who had participated in any clinical trial in the last 12 weeks
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MAKOTO KAWASHIMA</last_name>
    <role>Study Director</role>
    <affiliation>Tokyo Women's Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Corporation Kojinkai Asanuma Dermatology Clinic</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Kawashima M; Ichimura M; Yano K; Susuta Y; Izaki H. Phase III study of bepotastine besilate in children with atopic dermatitis －A randomized, double-blind, parallel-group, comparative study with ketotifen fumarate dry syrup－ Rinsho iyaku 2015 Mar;31(3):235-251</citation>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 17, 2015</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <firstreceived_results_date>September 17, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketotifen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TAU-284</title>
          <description>TAU-284 10mg twice daily for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Ketotifen Fumarate</title>
          <description>Ketotifen fumarate dry syrup 1g twice daily for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TAU-284</title>
          <description>TAU-284 10mg twice daily for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Ketotifen Fumarate</title>
          <description>Ketotifen fumarate dry syrup 1g twice daily for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="151"/>
                <measurement group_id="B2" value="152"/>
                <measurement group_id="B3" value="303"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10.2" spread="2.3"/>
                <measurement group_id="B2" value="10.4" spread="2.5"/>
                <measurement group_id="B3" value="10.3" spread="2.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="79"/>
                <measurement group_id="B2" value="62"/>
                <measurement group_id="B3" value="141"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="72"/>
                <measurement group_id="B2" value="90"/>
                <measurement group_id="B3" value="162"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pruritus Score</title>
        <description>The pruritus symptoms score were rated on 5-point scale ranging from 0 (none) to 4 (severe).</description>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>TAU-284</title>
            <description>TAU-284 10mg twice daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ketotifen Fumarate</title>
            <description>Ketotifen fumarate dry syrup 1g twice daily for 2 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="151"/>
                  <measurement group_id="O2" value="152"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Pruritus Score</title>
            <description>The pruritus symptoms score were rated on 5-point scale ranging from 0 (none) to 4 (severe).</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.669" spread="0.058"/>
                  <measurement group_id="O2" value="-0.638" spread="0.058"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pruritus Score</title>
        <time_frame>2 ｗeeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Atopic Dermatitis</title>
        <time_frame>2 ｗeeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Impression of Pruritus</title>
        <time_frame>2 ｗeeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TAU-284</title>
          <description>TAU-284 10mg twice daily for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Ketotifen Fumarate</title>
          <description>Ketotifen fumarate dry syrup 1g twice daily for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials, Information Desk</name_or_title>
      <organization>Mitsubishi Tanabe Pharma Corporation</organization>
      <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
